Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1111/bjh.19146
Keywords
autoimmune haemolytic anaemia; Evans syndrome; orelabrutinib; refractory; relapsed
Categories
Ask authors/readers for more resources
Currently, there is no effective treatment for refractory/relapsed autoimmune haemolytic anaemia. A clinical trial on orelabrutinib treatment showed positive results for some patients, suggesting it may become a new second-line treatment.
Currently, there is no effective treatment for refractory/relapsed (R/R) autoimmune haemolytic anaemia (AIHA), associated with poor quality of life. Bruton tyrosine kinase inhibitors have begun to be used in some autoimmune diseases. We initiated the clinical trial of orelabrutinib treatment on R/R AIHA/Evans Syndrome, which is in progress. The preliminary results showed that nine of the 12 enrolled patients responded to orelabrutinib treatment. Here, we reported three cases who have completed the treatment and were followed up for 6 months, achieving complete or partial remission. Orelabrutinib is expected to become a new second-line treatment for R/R AIHA/Evans syndrome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available